Specialized diagnostics OncoPlex Diagnostics offers CAP-accredited, CLIA-certified molecular diagnostics with a unique proteomics workflow that solubilizes tumor proteins from FFPE tissue for mass spectrometry analysis, combined with concurrent genomic sequencing from the same biopsy. This positions the company as a premier partner for labs seeking integrated proteomic and genomic tumor profiling.

High value offering The dual capability to deliver both targeted proteomic and genomic results from a single sample can streamline workflows, reduce tissue requests, and accelerate treatment decisions, presenting a compelling value proposition to oncologists, cancer centers, and hospitals looking for comprehensive diagnostics.

Quality and compliance With CAP accreditation and CLIA certification, the company demonstrates recognized quality standards, which can de-risk partnerships for healthcare systems and payer negotiations, especially when entering new markets or expanding reference laboratory services.

Tech-enabled operations Leveraging Microsoft 365, Azure, and related tech stack suggests scalable, cloud-enabled collaboration and data management capabilities that can be marketed to larger hospital networks and multi-site clinics seeking integrated IT and reporting solutions.

Growth opportunities Revenue in the lower mid-market range and a service model aligned with next-gen sequencing alongside proteomics open doors for collaborations with mid-to-large diagnostics firms, hospital systems, and cancer centers looking to augment or eventually replace more fragmented testing pipelines.